Streetbeat News

Price Targets

RMD

Morgan Stanley analyst Sean Laaman has upgraded ResMed (NYSE:RMD) from Equal-Weight to Overweight and set a price target of $169.

Portfolio Pulse from Benzinga Newsdesk

October 27, 2023 | 12:48 pm

AAP

Morgan Stanley analyst Simeon Gutman has maintained an Equal-Weight rating on Advance Auto Parts (NYSE:AAP) but lowered the price target from $75 to $55.

Portfolio Pulse from Benzinga Newsdesk

October 27, 2023 | 12:46 pm

LSCC

Rosenblatt analyst Hans Mosesmann has reiterated a 'Buy' rating on Lattice Semiconductor (NASDAQ:LSCC) and maintained a price target of $110.

Portfolio Pulse from Benzinga Newsdesk

October 27, 2023 | 12:35 pm

AMZN

HAS

HSY

HUBG

INTC

MA

PLXS

PTCT

RBLX

RF

Several Wall Street analysts have updated their outlooks on various stocks. Barclays cut Hub Group's price target from $80 to $75, while Needham increased Plexus Corp's target from $107 to $113. Citigroup slashed PTC Therapeutics' target from $29 to $17, and B of A Securities reduced Hasbro's target from $90 to $53. Rosenblatt increased Amazon's target from $184 to $185, and TD Cowen cut Hershey's target from $235 to $200. JP Morgan slashed Regions Financial's target from $19 to $16.5, while Truist Securities raised Roblox's target from $35 to $37. HSBC boosted Intel's target from $27 to $33, and Keybanc cut Mastercard's target from $440 to $430.

Portfolio Pulse from Lisa Levin

October 27, 2023 | 12:07 pm

INTC

Rosenblatt analyst Hans Mosesmann has reiterated a 'Sell' rating on Intel (NASDAQ:INTC) and maintained a price target of $17.

Portfolio Pulse from Benzinga Newsdesk

October 27, 2023 | 11:59 am

MPWR

Rosenblatt analyst Hans Mosesmann has reiterated a 'Buy' rating on Monolithic Power Systems (NASDAQ:MPWR) and maintained a price target of $580.

Portfolio Pulse from Benzinga Newsdesk

October 27, 2023 | 11:51 am

BMY

Barclays analyst Carter Gould has maintained an Equal-Weight rating on Bristol-Myers Squibb (NYSE:BMY) and lowered the price target from $60 to $51.

Portfolio Pulse from Benzinga Newsdesk

October 27, 2023 | 11:47 am

BPMC

Barclays analyst Peter Lawson maintains an Equal-Weight rating on Blueprint Medicines (NASDAQ:BPMC) and raises the price target from $46 to $58.

Portfolio Pulse from Benzinga Newsdesk

October 27, 2023 | 11:45 am

BKR

Barclays analyst David Anderson maintains an Overweight rating on Baker Hughes (NASDAQ:BKR) and raises the price target from $42 to $43.

Portfolio Pulse from Benzinga Newsdesk

October 27, 2023 | 11:43 am

AMZN

Barclays analyst Ross Sandler maintains an Overweight rating on Amazon.com (NASDAQ:AMZN) and raises the price target from $180 to $190.

Portfolio Pulse from Benzinga Newsdesk

October 27, 2023 | 11:41 am